Oculis Holding AG Ordinary shares (OCS)

FairStock Score: 42/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look for durable businesses with predictable earnings and a margin of safety. Oculis is a clinical-stage biotech developing OCS-01, OCS-02 and OCS-05 for ophthalmic and neuro-ophthalmic diseases. There is no product revenue in the data provided, and trailing free cash flow is -$65.9M, a -4.3% FCF yield on the $1.5B market cap. The shares closed at $7.62 on 2026-10-13, near the 52-week low of $7.32 and far below the high of $34.47. FairStock's calculations show a negative P/E of -4.56 and P/B of 1.76, so the multiple tells us little except that earnings are negative. FairStock's calculations also show ROE of -43.70% and ROCE of -24.95%, meaning capital is being consumed, not compounded. Debt/equity is only 0.01, and the Altman Z-score of 28.54 suggests low measured bankruptcy risk, but the Piotroski F-score of 2/9 reflects weak financial fundamentals. A moat cannot be assessed before approvals, reimbursement and commercial scale. Growth here is pipeline-driven, not a filed earnings record; FairStock cannot assign a Lynch category because there are zero years of filed results and it needs three. The price near lows may reflect clinical risk and future dilution. As Graham might say, the margin of safety is not in current earnings; it is in the probability-weighted pipeline. I would not mistake this for a Buffett-style compounder today. It is a speculative biotech whose value depends on trial success.

In plain English: Oculis is a small biotech company testing eye-disease medicines, and it does not yet have a marketed product mentioned. It is losing money and burning cash, so the business looks early and financially weak today. At about $7.62 a share, the price is near its 52-week low, but without profits or stated revenue it looks speculative rather than clearly cheap.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer